April 2021 | Report Format: Electronic (PDF)
Amyotrophic Lateral Sclerosis Treatment Market Growth & Trends
The global amyotrophic lateral sclerosis treatment market size is expected to reach USD 885.5 million by 2026, according to a new report by Grand View Research. Some of the key factors driving the market include growing awareness about ALS, increasing incidence rate, and rising geriatric population. However, the cost associated with ALS treatment is high, which may hinder the market growth during the forecast period.
Currently, no cure is available for ALS and treatments such as medications and stem cell therapies can only help to slow down the disease progression, manage the symptoms, and prevent unnecessary complications. Furthermore, inclination towards a sedentary lifestyle among the geriatric population increases the risk of developing the disorder that increases the demand for new targeted treatment options and therapeutic approaches. According to the U.S. Department of Health Resources & Services, the estimated prevalence of amyotrophic lateral sclerosis in the U.S. was 5.2 per 100,000 people and 16,583 cases of ALS were reported in 2015.
Among the treatments, the medications acquired the largest market share in 2018 and is expected to dominate the ALS market over the forecast period. Currently, only two drugs have been approved for use in ALS treatment, Rilutek (riluzole) and Radicava (edaravone). Nuedexta (dextromethorphan/quinidine) in another drug used in ALS treatments, however, it has been approved to treat the pseudobulbar affect (PBA), a comorbidity of ALS. North America held the leading position in the amyotrophic lateral sclerosis market in 2018, while Asia Pacific is projected to grow the fastest among all regions through the forecast period.
Request a free sample copy or view report summary:
Amyotrophic Lateral Sclerosis Treatment Market Report
Amyotrophic Lateral Sclerosis Treatment Market Report Highlights
- Medications held the largest market share in the treatment segment. Although, there is no cure for ALS, the approved medications such as riluzole and edaravone help in managing symptoms and delaying the disease progression.
- Stem cell therapy is expected to demonstrate the highest CAGR among the treatment over the forecast period due to the increasing demand for new approaches and advanced treatment options
- Asia Pacific regional market is projected to demonstrate the fastest growth during the forecast period due to rising disposable income and improving healthcare infrastructure
- Some of the major companies operating in this market include Mitsubishi Tanabe Pharma Corporation, Otsuka Pharmaceutical Co., Ltd., BrainStorm Therapeutics, Biogen Inc., Corestem, AB Science, F. Hoffmann-La Roche AG, Biohaven Pharmaceutical, Sun Pharmaceutical, and Ionis Pharmaceuticals, Inc.